Medical Dialogues

Women More Likely to Develop Chronic Rhinosinusitis Without Polyps, Finds New Study

Women aged 60 years or older had a 32% higher likelihood of CRSsNP diagnosis (OR 1.32). Women had a 37% lower chance of being ...

Insmed Incorporated (INSM) Q3 2025 Earnings Call Transcript

Today's call will feature prepared comments by Will Lewis, Chair and Chief Executive Officer; Roger Adsett, Chief Operating Officer; and Sara Bonstein, Chief Financial Officer. After their comments, ...

Women have higher odds of chronic rhinosinusitis without nasal polyps

Females have a higher odds of chronic rhinosinusitis (CRS) without nasal polyps than men, according to a study published ...

FDA approves Tezspire for chronic rhinosinusitis with nasal polyps

The U.S. Food and Drug Administration approved Tezspire (tezepelumab-ekko; Amgen) for the add-on maintenance treatment of inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) in ...
Clinical Advisor

Tezspire Gains Approval for Chronic Rhinosinusitis With Nasal Polyps

The approval for the CRSwNP indication was based on data from the randomized, double-blind, placebo-controlled WAYPOINT trial.
The American Journal of Managed Care

Tezepelumab Becomes First TSLP-Targeting Biologic Approved by FDA for CRSwNP

The FDA approved tezepelumab-ekko (TEZSPIRE; AstraZeneca/Amgen) on Friday as an add-on maintenance treatment in patients aged ...
Share Prices

Amgen and AstraZeneca says US FDA broadens indication for Tezspire

In a statement, Thousand Oaks, California-based Amgen and Cambridge, England-based AstraZeneca said Tezspire has been approved for the add-on maintenance treatment of inadequately controlled chronic ...

US FDA expands use of Amgen, AstraZeneca's drug for chronic inflammatory sinus disease

The U.S. Food and Drug Administration has approved Amgen and AstraZeneca's drug for a type of chronic inflammatory sinus ...

FDA Approves Amgen and AstraZeneca Treatment for Nasal Polyps Condition

The FDA approved Amgen's and AstraZeneca's drug to treat chronic rhinosinusitis with nasal polyps, an inflammatory condition of the sinuses and nasal passages. The companies said the approval was ...
The Joplin Globe

TEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps

AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab -ekko) has been approved in the US for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with inadequately ...
Morningstar

FDA APPROVES TEZSPIRE® FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS

THOUSAND OAKS, Calif., Oct. 17, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) approved TEZSPIRE® (tezepelumab-ekko) for the ...

Groton woman undergoes surgery for new nose following skin cancer diagnosis

Looking at her own reflection has a new meaning for Ginny Williamson.  “I look in the mirror every morning. I have a nose. You know? Where before I had nothing, nothing,” Ginny Williamson of Groton ...